Indies Pharma Jamaica Limited (INDIES), for the nine months ended July 31, 2022, reported revenue of $727.63 million, 15% higher than the $633.30 million booked in 2021. For the third quarter, revenue closed at $264.74 million (2021: $207.64 million).

Cost of sales declined by 10% to close at $210.26 million (2021: $233.18 million). This resulted in gross profit increasing by 29%, amounting to $517.37 million for the nine months relative to $400.11 million reported in the previous corresponding period. For the third, gross profit closed at $181.84 million (2021: $143.99 million).

Other operating income, decreased by 50% to close at $1.73 million (2021: $3.42 million).

Additionally, administrative and other expenses increased by 13% moving from $250.87 million in 2021 to $282.25 million in 2022.  For the quarter, administrative and other expenses closed at $91.08 million (2021: $85.20 million).

As such, operating profit for the period rose by 55% totalling $236.84 million (2021: $152.66 million). For the quarter, operating profit amounted to $91.75 million versus $61.86 million recorded in the prior comparable quarter.

Exchange loss amounted to $4.08 million relative to a gain of $2.58 million booked in the 2021. Finance cost declined to $45.05 million (2021: $51.66 million).

Profit before taxation increased by 81% to close at $187.71 million (2021: $103.58 million). For the quarter, profit before taxation amounted to $72.76 million (2021: $42.58 million).

Net profit for the period closed at $187.71 million (2021: $103.58 million). While for the quarter, net profit totalled $72.76 million (2021: $42.58 million).

Total comprehensive income for the period amounted to $188.36 million (2021: $105.98 million) and closed at $73.41 million (2021: $42.58 million ) for the quarter ended July 31, 2022.

Consequently, earnings per share (EPS) for the nine months amounted to $0.141 (2021: $0.078). While for the quarter, EPS closed at $0.055 (2021: $0.032). The trailing twelve months earnings per share amounted to $0.197.  The numbers of shares used in the calculations are 1,332,536,649 units. Notably, INDIES stock price closed the trading period on September 9, 2022 at $3.00 with a corresponding P/E of 15.22 times.

Balance Sheet at a glance:

As at July 31, 2022, the Company’s total asset base amounted to $2.17 billion (2021: $1.73 billion). The increase was mainly due to a 46% rise in ‘Property, plant and equipment’ to $949.75 million (2021: $648.84 million) and 38% rise in ‘Intangible assets’ to $370.19 million (2021: $268.45 million).

Equity attributable to stockholders amounted to $1.14 billion (2021: $746.14 million) with book value per share amounting to $0.86 (2021: $0.56).

Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.